Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroblastoma 5 Prostatic Neoplasms 2 Precancerous Conditions 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Osteosarcoma 1 Neoplasms 1 Medulloblastoma 1 Keratosis, Actinic 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Basal Cell 1 Adenomatous Polyps 1 Adenomatous Polyposis Coli 1

Interventions

Bevacizumab 45 Gemcitabine 44 Cyclophosphamide 40 Carboplatin 37 Docetaxel 35 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Doxorubicin 19 Pemetrexed 18 Drug Therapy 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636128 2014-07-30

Urinary Biomarker Study With Sulindac and Difluoromethylornithine

Cancer Prevention Pharmaceuticals, Inc.

Phase 2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡